Agenus to Present Phase II Study Data on Immunotherapy for Gastroesophageal Cancer at AACR 2026
Agenus Inc., a leader in immuno-oncology, announced that data from a Phase II trial will be presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026. The study, conducted at Memorial Sloan Kettering Cancer Center, evaluates the combination of botensilimab (BOT) and balstilimab (BAL) with agenT-797, an allogeneic iNKT cell therapy, in patients with PD-1 refractory gastroesophageal cancer. This cancer type presents significant treatment challenges due to resistance to checkpoint inhibitors. The presentation aims to provide insights into immune modulation, treatment sequencing, and response durability in hard-to-treat tumors. 
